The European Commission has approved Cenrifki (tolebrutinib) by Sanofi for treating secondary progressive multiple sclerosis (SPMS) without relapses, based on positive phase 3 trial results showing it delays disability progression. This is the first drug approved in the EU to specifically target the underlying progression of disability in SPMS patients without recent relapses. Cenrifki works by inhibiting brain-penetrant Bruton tyrosine kinase to reduce neuroinflammation, a key factor in SPMS progression. Sanofi plans to launch Cenrifki commercially in Germany this year, with close medical oversight and risk management to ensure patient safety, especially monitoring liver enzyme elevations linked to the drug.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
The FDA has approved Sarclisa Escena, a subcutaneous formulation of the multiple myeloma drug Sarclisa, administered via the innovative CirCLIQ on-body injector (OBI). This is the first anticancer treatment approved for delivery through an on-body in...
